Introduction
============

Cardiovascular disease is the leading cause of morbidity and mortality worldwide, resulting in an estimated 17 million deaths each year, particularly from myocardial infarction and stroke ([@b23]). The number of patients with renal disease who require dialysis is also currently high and is expected to double to 2 million by 2010 ([@b49]). Endothelial dysfunction is the initial pathophysiologic step in the cardiovascular--renal continuum, which is a progression of vascular damage that is triggered by risk factors such as hypertension and leads to both kidney failure and overt cardiovascular disease ([@b14]). Prospective studies have demonstrated that, in the peripheral and coronary circulation, endothelial dysfunction is highly predictive of future cardiovascular morbidity ([@b56]; [@b29]; [@b50]). Therefore, it has been hypothesized that treatment to reverse endothelial dysfunction may lead to a reduction in cardiovascular and renal events.

Blockade of the renin--angiotensin system (RAS) with angiotensin receptor blockers (ARBs) or angiotensin-converting enzyme (ACE) inhibitors has been shown to provide improved endothelial function in patients with type 2 diabetes and nephropathy (Karalliedde and Viberti 2006). These agents also reduce microalbuminuria, a marker of increased permeability due to endothelial dysfunction. Recent evidence suggests that there is no clear-cut difference between ARB and ACE inhibitor agents in their effects on endothelial dysfunction and low-grade albuminuria ([@b57]). Significant prospective data are essential to investigate whether improved endothelial function translates into reduced cardiovascular and renal events in high-risk patients, and to assess possible differential outcomes with ARBs, ACE inhibitors, or a combination of both (dual RAS blockade). The ONgoing Telmisartan Alone in combination with Ramipril Global Endpoint Trial (ONTARGET) Programme is expected to provide ultimate evidence of the risk reduction that can be achieved with these treatments.

This review will discuss the pathophysiology of endothelial dysfunction, its role in the cardiovascular--renal continuum, and the potential for improvements with RAS blockers. The expectations and possible clinical implications of the wealth of data due from ONTARGET will be considered.

Pathophysiology of endothelial dysfunction and its role in the cardiovascular--renal continuum
==============================================================================================

The endothelium is a major regulator of vascular homeostasis, and its functional integrity is essential for the maintenance of blood flow and antithrombotic activity ([@b14]; [@b18]). Endothelial cells, a monolayer between circulating blood and vascular smooth muscle, produce signaling molecules that modulate tone, monocyte adhesion, and platelet--neutrophil aggregation in the vascular smooth muscle cells. The balance between the actions of these signaling molecules is of critical importance. One important signaling molecule released by vascular endothelial cells is nitric oxide (NO), formed from L-arginine in the presence of NO synthase ([@b46]). NO is both a potent vasodilator and an inhibitor of platelet adhesion and aggregation, and exerts antifibrotic effects.

Endothelial dysfunction can be defined as an imbalance between vasodilating and vasoconstricting substances produced by (or acting on) endothelial cells ([@b14]). In particular, the dysfunctional endothelium is characterized by impaired NO synthesis or increased NO degradation. Potentially harmful effects include vasoconstriction, platelet aggregation, white blood cell adhesion, and proliferation of smooth muscle cells ([@b4]; [@b37]). The result is a reduction of regional or whole-organ perfusion, leading to target-organ damage and an increased incidence of ischemic events ([@b56]; [@b29]; [@b50]). Thus, endothelial dysfunction is an early marker of vascular disease, and leads to both cardiovascular and renal morbidity ([@b47]; [@b42]; [@b51]; [@b64]; [@b5]).

Endothelial dysfunction can be assessed by biochemical markers, molecular genetic tests and invasive or non-invasive techniques, although the optimal methodology is still unclear ([@b18]; [@b40]). Current biochemical markers include, for example, adhesion molecules ICAM-2, VCAM-1, E-selectin, P-selectin and sCD40L, cytokines interleukin 6, interleukin 18, hs-CRP and ET-1 ([@b18]). Genetic markers include von Willebrand factor (vWF), angiotensin I converting enzyme (ACE), preproendothelin (ET)-1, endothelin I converting enzyme (ECE-1), endothelin B receptor, eNOS, NF-κB, ICAM-1, VCAM-1, and E-selectin ([@b18]).

Non-invasive techniques include flow-mediated vasodilation (FMD) in the brachial or radial artery ([@b16]). Invasive procedures are forearm blood flow (FBF) by cannulation of the brachial artery ([@b47]) or for coronary circulation, an infusion of intracoronary acetylcholine (ACh) ([@b28]).

Recent evidence confirms that there is a close link between cardiovascular and renal changes, and that they are triggered by similar risk factors, such as hypertension, hyperglycemia, dyslipidemia, and obesity ([Figure 1](#fig1){ref-type="fig"}) ([@b32]; [@b3]; [@b61]). Mechanical and chemical damage resulting from these interrelated risk factors promote a general progression of vascular damage that begins with endothelial dysfunction and atherosclerosis, which leads to proteinuria, left ventricular hypertrophy, and transient ischemic attacks in the brain, then progresses to chronic kidney disease, overt cardiovascular disease, and stroke ([@b14]). This is known as the cardiovascular--renal continuum ([Figure 1](#fig1){ref-type="fig"}). It is now understood that cardiovascular prognosis is clearly reflected by measures of renal dysfunction, such as increased albuminuria and a decline in the glomerular filtration rate (GFR), with even modest changes markedly increasing the risk for cardiovascular disease ([@b25]; [@b32]; [@b3]; [@b7]). Thus, renal dysfunction is a risk factor for cardiovascular death. In fact, most patients with renal impairment die from cardiovascular causes, rather than from end-stage renal disease ([@b25]; [@b32]; [@b3]).

![The cardiovascular--renal continuum.](vhrm0301-001-01){#fig1}

Microalbuminuria occurs early in the cardiovascular--renal continuum, closely following endothelial dysfunction ([Figure 1](#fig1){ref-type="fig"}) ([@b21]). These small losses of protein in the urine develop when the loss of endothelial integrity in the kidney results in intraglomerular hypertension and inflammation ([@b36]). Microalbuminuria is frequently detected in individuals with atherosclerosis and has been found to be a risk factor for type 2 diabetes and cardiovascular disease ([@b25]; [@b32]; [@b3]; [@b7]; [@b12]). Thus, microalbuminuria is an early marker of widespread vascular, renal, and other target-organ damage.

The physiological actions of angiotensin II in cardiovascular, renal, neuronal, endocrine and hepatic systems are nearly all mediated by the angiotensin II receptor. Actions include, for example, the regulation of arterial blood pressure, electrolyte and water balance, and renal function ([@b19]). Angiotensin II is a potent arteriole vasoconstrictor which can increase total peripheral resistance thereby increasing arterial pressure. As the primary agent of the RAS, angiotensin II also has a central role in endothelial dysfunction ([Figure 2](#fig2){ref-type="fig"}) ([@b22]). In addition to increasing blood pressure, angiotensin II acts via the angiotensin II type 1 receptor (AT~1~) receptor to increase oxidative stress, causing NO breakdown ([@b20]; [@b69]). Elevated levels of Angiotensin II in the endothelium stimulates nicotinamide adenine dinucleotide phosphate (NADPH) and nicotinamide adenine dinucleotide (NADH) oxidase to generate reactive oxygen species (ROS) responsible for NO breakdown ([@b26]). This leads to endothelial dysfunction, cell growth, inflammation by the activation of nuclear factor-κB (NF-κB), monocyte chemoattractant protein-1 (MCP-1), vascular cell adhesion molecule (VCAM), and the release of the cytokines interleu-kin-6 (IL-6) and tumor necrosis factor-α (TNF-α) ([@b43]; [@b30]; [@b27]). VCAM and cytokine action increases the adhesiveness of the endothelium and subsequently the binding of inflammatory cells to the endothelial surface leading to vascular inflammation and thrombosis ([Figure 3](#fig3){ref-type="fig"}) ([@b39]; [@b57]). Thus, angiotensin II is involved in every step of the cardiovascular--renal continuum, promoting a wide variety of deleterious effects on target organs.
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![Schematic representation of the multiple effects of increased tissue production of angiotensin II. Reprinted from Schmieder RE, 2005. Mechanisms for the clinical benefits of Angiotensin II receptor blockers. *Am J Hypertens,* 18:720--30. Copyright © 2005, with permission from American Journal of Hypertension, Ltd.\
**Abbreviations**: ET-1, endothelin-1; MCP-1, monocyte chemoattractant protein-I; MMP, matrix metalloproteinase; NF-~k~B, nuclear factor-~k~B; NO, nitric oxide; PAI-1, plasminogen activator type 1;VCAM, vascular cell adhesion molecule;ACE, angiotensin-converting enzyme.](vhrm0301-001-03){#fig3}

![Improved endothelial function with telmisartan compared with ramipril in the TRENDY study. From Schmieder et al. 2005. Effects of telmisartan versus ramipril on endothelium function of the renal vasculature in type 2 diabetes. *J Hypertens,* 23:S147.](vhrm0301-001-04){#fig4}

RAS blockade to reverse endothelial dysfunction
===============================================

In addition to blood pressure-lowering effects, RAS blockade with an ARB and/or ACE inhibitor provides a rational approach to reversing endothelial dysfunction by reducing the harmful effects of angiotensin II ([@b35]). Such treatments may provide cardiovascular and renal protection beyond that of reducing a single cardiovascular risk factor. Indeed, current clinical guidelines recommend ARBs as first-line treatment in patients with type 2 diabetes and nephropathy ([@b2]).

ARBs and ACE inhibitors act at different points in the RAS pathway ([Figure 2](#fig2){ref-type="fig"}). ACE inhibitors prevent the generation of angiotensin II, which subsequently can activate both AT~1~ and angiotensin II type 2 (AT~2~) receptors ([@b15]). ACE inhibitors also inhibit the breakdown of bradykinin by kinase II, thereby increasing bradykinin levels. This may cause vasodilation, thereby decreasing blood pressure, and may improve endothelial function ([@b17]). However, bradykinin and the structurally related substance P can also potentially cause cough, a side effect that many patients find unacceptable ([@b17]). In addition, ACE inhibitors can allow continued activation of AT~1~ by angiotensin II via alternative pathways, a phenomenon known as "angiotensin II escape" ([@b53]). During long-term therapy, angiotensin II concentrations can revert to pretreatment levels, thus attenuating the protective effect of ACE inhibition. Angiotensin II escape may be a particular problem for the local kidney RAS, in which up to 40% of angiotensin II formation is via non-ACE pathways ([@b33]). This may explain why ACE inhibitors do not reduce levels of angiotensin II in the renal interstitial fluid ([@b45]). ACE inhibitors and vascular diseases has recently been reviewed by [@b44]).

In contrast to ACE inhibitors, ARBs are highly selective for the AT~1~ receptor, which is believed to be responsible for the pathophysiologic effects of angiotensin II ([@b15]). The AT~2~ receptor generally has effects opposed to those of AT~1~ and is abundantly expressed in endothelial cells ([@b6]) ([Figure 2](#fig2){ref-type="fig"}). ARBs do not increase bradykinin levels and are, therefore, not associated with cough. Furthermore, ARBs maintain selective blockade of AT~1~ and are, thus, not associated with angiotensin II escape.

Telmisartan is a potent selective once-daily ARB that provides a sustained blood pressure-lowering effect over 24 hours ([@b11]). As discussed below, studies have shown that telmisartan also reduces target-organ damage, including improvements in endothelial dysfunction ([@b62]; [@b57]; [@b63]), arterial stiffness ([@b8]; [@b66]), the progression of renal dysfunction in patients with type 2 diabetes ([@b9]), proteinuria ([@b52]; [@b54]; [@b59]), and left ventricular hypertrophy ([@b24]; [@b34]). In clinical trials, other ARBs have also demonstrated effective renoprotection in patients with type 2 diabetes and renal disease ([@b13]; [@b41]; [@b48]; [@b67]; [@b38]). These trials showed that ARBs can reverse microalbuminuria, suppress the progression of albuminuria and loss of renal function, and prevent progression to end-stage renal disease.

RAS blockade with ACE inhibitors may demonstrate favorable effects on the endothelium. In short-term clinical studies, ACE inhibitors reduced microalbuminuria and, in the longer term, they are superior to non-RAS-targeting antihypertensive agents in maintaining normal renal function ([@b1]). In one study, hypertensive patients receiving ACE inhibitors displayed improved maximal forearm blood flow response to hyperemia that was significantly greater (p \< 0.05) than the response in patients treated with calcium channel blockers, β-blockers, or diuretics ([@b31]).

Improved endothelial function with telmisartan
==============================================

The Telmisartan versus Ramipril in renal ENdothelial DYsfunction (TRENDY) study showed that both telmisartan and ramipril improved endothelial function (increased NO activity) in patients with type 2 diabetes and hypertension ([@b57]). TRENDY was the first head-to-head comparison of the effect of an ARB versus an ACE inhibitor on endothelial function. In a prospective, randomized, double-blind, forced-titration design, 96 patients with type 2 diabetes, normoalbuminuria or microalbuminuria, thus early-stage nephropathy, were randomized to 9 weeks' treatment with telmisartan 40--80 mg or ramipril 5--10 mg, with add-on therapy (hydrochlorothiazide, metoprolol, or atenolol) to achieve blood pressure control. The primary end point was renal plasma flow in response to *N*-monomethyl-[L]{.smallcaps}-arginine ([L]{.smallcaps}-NMMA) infusion. Telmisartan significantly increased the response of renal plasma flow to [L]{.smallcaps}-NMMA infusion (p \< 0.001 vs baseline) taken as an indicator of NO activity ([Figure 4](#fig4){ref-type="fig"}) ([@b57]). At rest (ie, without the stimulus), telmisartan also significantly improved (p \< 0.05) renal plasma flow (by 27.3 mL/min) and reduced renal vascular resistance (by 7%). In addition, although levels of albuminuria were low at baseline, telmisartan significantly improved (p \< 0.05) albuminuria (reduced from 9.0 to 7.2 mg/24 hours). Ramipril also increased the response of renal plasma flow to [L]{.smallcaps}-NMMA infusion (p \< 0.02 versus baseline) but, in contrast to telmisartan, the ACE inhibitor ramipril did not improve renal plasma flow or reduced renal vascular resistance significantly.

In a 3-month, double blind, cross-over study, endothelial function was improved by telmisartan 40 mg but to a lower extent by ramipril 2.5 mg in 40 non-hypertensive patients with controlled type 2 diabetes without coronary artery disease, left ventricular dysfunction, or microalbuminuria ([@b63]). Brachial artery flow-mediated dilation was improved 96% by telmisartan compared with only 36% by ramipril. Interestingly, the combination of telmisartan and ramipril increased dilation by 111%. Tissue plasminogen activator and von Willebrand factor, measures of endothelial health and fibrinolytic status, were improved in this study, with the combination of the ARB and the ACE inhibitor again producing the greatest benefit. Telmisartan has also been shown to improve endothelial function in treatment-naïve hypertensive patients with chronic heart failure ([@b62]).

Decline in GFR is an important sign of renal damage. The Diabetics Exposed to Telmisartan And enalaprIL (DETAIL) study showed that both telmisartan and the ACE inhibitor enalapril similarly reduced the decline in GFR over 5 years in patients with hypertension and early type 2 diabetic nephropathy ([@b9]). In a prospective, randomized, double-blind, forced-titration design, 250 patients were randomized to telmisartan 40--80 mg or enalapril 10--20 mg, each with add-on therapy to control blood pressure. After the first year, both treatments reduced GFR decline with a consistent, year-on-year effect. By year 3, the annual decline in GFR stabilized to approximately 2 mL/min/1.73 m^2^. This is substantially lower than the annual decline of 10--12 mL/min/1.73 m^2^ that is observed in untreated diabetic patients with proteinuria ([@b10]). There were no significant differences in blood pressure lowering between the groups.

Clinical studies have consistently shown that telmisartan reduces proteinuria ([@b52]; [@b54]; [@b59]). A 12-month study of 206 patients assessed the interactions between RAS gene polymorphisms and telmisartan therapy in patients with mild-to-moderate hypertension ([@b52]). Microalbuminuria was present in 28% of patients, and mean urinary albumin excretion was 32.7 mg/day. Telmisartan treatment significantly reduced albuminuria by 69% by month 12. The effects of 3 months' treatment with telmisartan 40--80 mg/day were examined in 92 patients with hypertension (60 with diabetes), serum creatinine \<350 µmol/L, and proteinuria \>1 g/day ([@b54]). Telmisartan reduced proteinuria by 21%; corresponding to a decrease of 0.76 g/24 hours from 3.62 g/24 hours.

Telmisartan, when given in addition to the ACE inhibitor lisinopril, provided further reductions in the albumin excretion compared with ACE inhibitor monotherapy ([@b59]). Patients with type 2 diabetes and micro-albuminuria (n = 219) had been receiving ACE inhibitors for at least 6 months previously, then received either telmisartan 80 mg or lisinopril 20 mg monotherapy for a further 6 months. Half of the patients then received combination therapy with telmisartan 80 mg/lisinopril 20 mg. At 6 months, reductions in albuminuria were 31% with telmisartan and 37% with lisinopril. After 12 months, telmisartan had reduced albuminuria by an additional 30%. Similar results were seen in the group in which lisinopril was added to telmisartan. Both treatments produced comparable reductions in blood pressure, supporting the notion that the further reduction of proteinuria was blood pressure independent.

Arterial stiffness is an early sign of atherosclerosis and an important risk factor for cardiovascular disease ([@b55]). In one study of arterial stiffness, 24 patients with hypertension received telmisartan 40 mg for 3 months ([@b66]). Brachial-ankle pulse wave velocity was reduced by 12% from 18.92 m/s at baseline to 16.72 m/s (p \< 0.01). The improvement in pulse wave velocity was greater than predicted on the basis of the reduction in blood pressure observed. In another study, telmisartan significantly reduced arterial stiffness, measured by carotid-femoral pulse wave velocity, compared with placebo in 28 patients with type 2 diabetes and hypertension ([@b8]).

The ONTARGET trial
==================

The ONTARGET Trial Programme is comparing telmisartan, ramipril, and the combination of both antihypertensive agents in the prevention of cardiovascular morbidity and mortality in patients at high risk ([@b65]). Telmisartan was the ARB selected for The ONTARGET Trial Programme because it provides sustained antihypertensive activity effect over the 24-hour period between doses ([@b11]). The comparator, the ACE inhibitor ramipril, was selected because in the Heart Outcomes Protection Evaluation (HOPE) trial, it was proven to reduce the incidence of cardiovascular events in a similar patient population (55 years of age or older, with evidence of vascular disease or diabetes plus one other cardiovascular risk factor and who were not known to have a low ejection fraction or heart failure) ([@b68]). Patients enrolled in ONTARGET have vascular disease (coronary artery disease, peripheral arterial occlusive disease, or stroke), or diabetes with end-organ damage ([@b65]). The primary outcome is a composite end point of cardiovascular death, stroke, acute myocardial infarction, and hospitalization for chronic heart failure. A variety of renal end points have also been included. Telmisartan Randomized AssessmeNt Study in ACE-I-iNtolerant subjects with cardiovascular Disease (TRANSCEND) is a parallel study within The ONTARGET Trial Programme that is comparing the cardiovascular protective effect of telmisartan with placebo in patients intolerant to ACE inhibitors ([@b65]).

ONTARGET has several important features. The trial has recruited 25620 patients from 800 centers in 40 countries throughout Europe, North America, Africa, Australasia, and Asia ([@b65]), and findings will be based on more than 100 000 patient-years of data. This makes ONTARGET the largest ever randomized clinical trial to test the effects of an ARB versus an ACE inhibitor and of combination treatment of an ARB with an ACE inhibitor on cardiovascular risk reduction. Results from previous trials (see above) suggested that treatment with telmisartan or ramipril reduces the cardiovascular outcome to similar extent, with the combination to be superior. Thus, ONTARGET should provide the ultimate evidence regarding the cardiovascular benefit of different strategies to block the RAS in high-risk patients. Furthermore, TRANSCEND, which has enrolled 5926 patients, is the largest trial to evaluate the cardiovascular protective effects of telmisartan in patients with ACE inhibitor intolerance.

Baseline characteristics are now available for all patients recruited into the ONTARGET study ([@b55]). Importantly, patients have controlled hypertension (mean blood pressure at randomization was 134/77 mm Hg) and cardiovascular risk factors at baseline, and are thus representative of those seen in everyday clinical practice. Compared with the HOPE study, patients in ONTARGET have greater ethnic diversity, are slightly older, are more likely to have cerebrovascular disease and hypertension, and have increased statin use (60.7% and 28.9%, respectively). These differences reflect the changing approach to cardiovascular disease prevention.

The ONTARGET Trial Programme is the first long-term prospective trial to investigate the efficacy of an ARB/ACE inhibitor combination (dual RAS blockade). Due to the different mechanisms of action of telmisartan and ramipril, there is the potential for differential cardiovascular outcomes, independent of their effects on blood pressure. The combination may be able to fully suppress the deleterious effects of angiotensin II and, at the same time, provide additive improvements in renal bradykinin and cyclic guanosine monophosphate, two molecules that improve endothelial function ([@b60]). Therefore, the combination may offer superior cardiovascular protection compared with either monotherapy as a result of their complementary effects.

Predefined substudies should provide greater understanding of differences in the cardiovascular risk reduction achieved by RAS blockade with telmisartan, ramipril, and the combination ([@b55]). The incidence and time course of erectile dysfunction is being evaluated during drug treatment in 1500 patients from both ONTARGET and TRANSCEND. Previous studies have shown that erectile dysfunction is caused by premature atherosclerosis and such antihypertensive drugs as β-blockers and diuretics ([@b14]). Therefore, the choice of antihypertensive medication appears to be critical. Furthermore, drugs known to improve or delay endothelial dysfunction may have a positive impact on erectile dysfunction. The substudy of ONTARGET/TRANSCEND will assess whether erectile dysfunction is related to cardiovascular risk factors and to the use of cardioprotective drugs. The primary end point is the onset of change of erectile dysfunction, assessed using the modified "Cologne Male Survey" questionnaire, in patients receiving placebo, telmisartan, ramipril, or both active agents.

In another substudy, 284 patients enrolled in TRANSCEND will undergo evaluation of arterial stiffness. As mentioned above, telmisartan has proven benefits on arterial stiffness in patients with type 2 diabetes and hypertension ([@b8]; [@b66]). The arterial stiffness substudy of TRANSCEND will answer the question of whether changes in arterial stiffness correlate with clinical outcome. The primary end point is change in aortic stiffness determined by carotid-femoral pulse wave velocity. As a secondary end point, the predictive value of early, short-term changes in arterial stiffness on the long-term clinical outcome of patients is being evaluated.

Conclusions
===========

The ONTARGET Trial Programme is due to be completed in 2008, and results are expected to provide clinicians with a wealth of data to improve evidence-based treatment of patients at high risk of cardiovascular events. By blocking the RAS, ACE inhibitor and ARB treatment may, in addition to blood-pressure lowering, have positive effects on endothelial function, the initial step in vascular damage. This should provide greater benefits than treating individual cardiovascular risk factors. With over 100000 patient-years of data, the pro-gram is expected to provide the ultimate evidence for whether improved endothelial function does indeed translate into reduced cardiovascular and renal events in high-risk patients. In addition, the trial will establish whether treatment with the ARB telmisartan, the ACE inhibitor ramipril, and dual RAS blockade with both agents is associated with differential cardiovascular/renal outcomes. Due to its high selectivity for the AT~1~ receptor, telmisartan may prove to exert excellent cardiovascular protection. The complementary mechanisms of action of telmisartan and ramipril may lead to superior cardiovascular protection with the combination compared with either monotherapy. Thus, the ONTARGET data are expected to have a substantial impact on clinical practice by allowing physicians to choose the optimal treatment regimen to protect their patients at risk of future cardiovascular or renal morbidity and mortality.
